The Latest Cardiac and Vascular News
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam […]
AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM DUBLIN, May 16, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program as the “Best […]
Patent Underscores AI for Vectorcardiography (VECG) IP Leadership Effort SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received a notice of allowance from The United […]
The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, with all three studies underway RARITAN, N.J., May 25, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three […]
Case study of patient save also presented at Heart Rhythm 2023 SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced the completion of enrollment in its Jewel IDE Study (NCT05201495). A case study was also […]
For the second consecutive year, Eko Health honored with Fast Company’s World Changing Ideas Awards and Inc. Magazine’s Best Workplaces OAKLAND, Calif., May 23, 2023 /PRNewswire/ — Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced that it has been honored in Fast Company’s World Changing […]
Abbott’s AVEIR™ DR i2i™ IDE study is the industry’s first prospective study on the safety and performance of the world’s first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott’s investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the […]
Clinical studies presented at Heart Rhythm 2023 build on the totality of clinical evidence that continue to highlight the value of iRhythm’s Zio products and services across a wide range of patient populations SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) — Rhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused […]
Late-breaking data at Heart Rhythm 2023 underscore performance of first-of-its-kind investigational defibrillator with the lead placed under the breastbone, outside the heart and veins Additionally, real-world analysis confirms long-term therapeutic benefit of commercially available ICDs DUBLIN and NEW ORLEANS, May 20, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced longer-term […]
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness endpoints MARLBOROUGH, Mass., May 20, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company’s key electrophysiology […]
